Keyphrases
Phase II Study
100%
Neoadjuvant Therapy
100%
Trastuzumab
100%
ER +
100%
Letrozole
100%
Palbociclib
100%
HER2+ Breast Cancer
100%
Pathological Complete Response
80%
Ki-67
60%
RNA Sequencing (RNA-seq)
40%
Human Epidermal Growth Factor Receptor 2 (HER2)
40%
Chemotherapy
40%
Neoadjuvant
40%
PAM50
40%
Hypertension
20%
MTORC1 Signaling
20%
Whole Exome Sequencing
20%
Cell Cycle Arrest
20%
Neutropenia
20%
Cell Proliferation
20%
Research Biopsy
20%
Treatment-related Adverse Events
20%
Endocrine Therapy
20%
Leukopenia
20%
Differentially Expressed
20%
Molecular Signature
20%
ER Signaling
20%
DNA Damage Repair
20%
MKI67
20%
Gene Analysis
20%
Antiproliferative Activity
20%
Cyclin-dependent Kinase 4 (CDK4)
20%
Luminal B
20%
Aurora Kinase A (AURKA)
20%
Polo-like Kinase 1 (PLK1)
20%
Residual Cancer
20%
Patient Accrual
20%
Drug Mechanism of Action
20%
Dual HER2 Blockade
20%
CCNB1
20%
Signature Database
20%
Pharmacology, Toxicology and Pharmaceutical Science
Trastuzumab
100%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
100%
Palbociclib
100%
Letrozole
100%
Chemotherapy
40%
RNA-Sequencing
40%
Malignant Neoplasm
20%
Neutropenia
20%
Adverse Event
20%
Endocrine Therapy
20%
Leukopenia
20%
Drug Action
20%
Biochemistry, Genetics and Molecular Biology
Trastuzumab
100%
Letrozole
100%
RNA Sequence
40%
Subtyping
40%
Exome Sequencing
20%
Cell Cycle Arrest
20%
DNA Repair
20%
Cell Proliferation
20%
Drug Mechanism
20%
Cell Cycle Checkpoint
20%
Antiproliferative Activity
20%
PLK1
20%
Immunology and Microbiology
Trastuzumab
100%
RNA Sequence
40%
DNA Repair
20%
Cell Proliferation
20%
Whole Exome Sequencing
20%
Cell Cycle Arrest
20%
Cell Cycle Checkpoint
20%
Antiproliferative Activity
20%
Drug Mechanism
20%